HeimPRRUF • OTCMKTS
add
Immutep Ltd
Við síðustu lokun
0,18 $
Árabil
0,17 $ - 0,28 $
Markaðsvirði
292,16 m. USD
Meðalmagn
500,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
ASX
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (AUD) | des. 2023info | Breyting á/á |
|---|---|---|
Tekjur | 1,06 m. | 25,23% |
Rekstrarkostnaður | 2,40 m. | 16,20% |
Nettótekjur | -10,61 m. | -2,93% |
Hagnaðarhlutfall | -1,01 þ. | 17,80% |
Hagnaður á hvern hlut | — | — |
EBITDA | -11,10 m. | -8,28% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (AUD) | des. 2023info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 103,73 m. | 51,71% |
Heildareignir | 123,79 m. | 43,92% |
Heildarskuldir | 8,15 m. | -12,60% |
Eigið fé alls | 115,64 m. | — |
Útistandandi hlutabréf | 1,19 ma. | — |
Eiginfjárgengi | 1,83 | — |
Arðsemi eigna | -23,35% | — |
Ávöxtun eigin fjár | -24,65% | — |
Peningaflæði
Breyting á handbæru fé
| (AUD) | des. 2023info | Breyting á/á |
|---|---|---|
Nettótekjur | -10,61 m. | -2,93% |
Handbært fé frá rekstri | -9,23 m. | -54,83% |
Reiðufé frá fjárfestingum | -209,56 þ. | -607,90% |
Reiðufé frá fjármögnun | -215,93 þ. | -278,22% |
Breyting á handbæru fé | -9,84 m. | -69,40% |
Frjálst peningaflæði | -6,90 m. | -2,37% |
Um
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
Framkvæmdastjóri
Stofnsett
2001
Vefsvæði
Starfsfólk
19
